{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peg-IFN-alfa-2a", "query": { "intervention": "Peg-IFN-alfa-2a" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 199, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peg-IFN-alfa-2a&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T09:16:04.240Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00402428", "title": "Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "albumin interferon alfa-2b", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Human Genome Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1331, "start_date": "2006-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2013-08-08", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402428" }, { "nct_id": "NCT01265511", "title": "Study of SCY-635, Pegasys and Copegus in Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Infection" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "SCY-635", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Copegus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scynexis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2010-11", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2017-08-18", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 3, "location_summary": "San Francisco, California • Durham, North Carolina • San Antonio, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Durham", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265511" }, { "nct_id": "NCT00987337", "title": "Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis", "Hepatitis C" ], "interventions": [ { "name": "Filibuvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 288, "start_date": "2009-11", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2014-01-27", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 30, "location_summary": "Anaheim, California • Coronado, California • La Jolla, California + 22 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Mather", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00987337" }, { "nct_id": "NCT05535764", "title": "AlloHCT With PegINFa for Myelofibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Pegylated interferon alpha2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2023-08-02", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05535764" }, { "nct_id": "NCT01808248", "title": "Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2013-02", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-09-12", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01808248" }, { "nct_id": "NCT01467492", "title": "Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 121, "start_date": "2012-01", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-08-03", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 27, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467492" }, { "nct_id": "NCT01598090", "title": "Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Peginterferon Lambda-1a", "type": "BIOLOGICAL" }, { "name": "Peginterferon Alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 881, "start_date": "2012-06-14", "completion_date": "2015-05-15", "has_results": true, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anaheim, California • Garden Grove, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598090" }, { "nct_id": "NCT00056862", "title": "Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2003-03", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2013-12-06", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056862" }, { "nct_id": "NCT00078403", "title": "Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C", "Liver Disease" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2004-07", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2021-11-08", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078403" }, { "nct_id": "NCT01188772", "title": "Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Placebo to match sofosbuvir", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 147, "start_date": "2010-08", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-09-29T09:16:04.240Z", "location_count": 22, "location_summary": "Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01188772" } ] }